Guochuan Tsai

List of Publications by Year
in descending order

35 papers	6,248 citations	201674 27 h-index	377865 34 g-index
36 all docs	36 docs citations	36 times ranked	5076 citing authors

#	Article	IF	Citations
1	Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Annals of Neurology, 1990, 28, 18-25.	5.3	604
2	D-serine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 1998, 44, 1081-1089.	1.3	586
3	Glutamatergic Mechanisms in Schizophrenia. Annual Review of Pharmacology and Toxicology, 2002, 42, 165-179.	9.4	569
4	Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains. Archives of General Psychiatry, 1995, 52, 829.	12.3	429
5	A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia. Archives of General Psychiatry, 1999, 56, 21.	12.3	410
6	Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia. Annals of the New York Academy of Sciences, 2003, 1003, 318-327.	3.8	402
7	N -Acetylaspartate in neuropsychiatric disorders. Progress in Neurobiology, 1995, 46, 531-540.	5.7	394
8	The Role of Glutamatergic Neurotransmission in the Pathophysiology of Alcoholism. Annual Review of Medicine, 1998, 49, 173-184.	12.2	375
9	Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 2004, 55, 452-456.	1.3	325
10	Strategies to Enhance N-Methyl-D-Aspartate Receptor-Mediated Neurotransmission in Schizophrenia, a Critical Review and Meta-Analysis. Current Pharmaceutical Design, 2010, 16, 522-537.	1.9	245
11	Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated With Tardive Dyskinesia. American Journal of Psychiatry, 1998, 155, 1207-1213.	7.2	231
12	The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology, 2004, 174, 32-8.	3.1	199
13	Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8485-8490.	7.1	192
14	Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia. Biological Psychiatry, 2006, 60, 645-649.	1.3	182
15	NMDA Receptor Function, Neuroplasticity, and the Pathophysiology of Schizophrenia. International Review of Neurobiology, 2004, 59, 491-515.	2.0	115
16	Reductions in acidic amino acids andN-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS. Brain Research, 1991, 556, 151-156.	2.2	105
17	Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biological Psychiatry, 2002, 51, 493-497.	1.3	104
18	A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology, 2005, 179, 144-150.	3.1	103

#	Article	IF	Citations
19	Ionotropic Glutamate Receptors as Therapeutic Targets in Schizophrenia. CNS and Neurological Disorders, 2002, 1, 183-189.	4.3	101
20	Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated ?-linked acidic dipeptidase (NAALADase). Journal of Comparative Neurology, 1992, 315, 217-229.	1.6	91
21	Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biological Psychiatry, 1998, 44, 667-674.	1.3	73
22	Calcium-Dependent Evoked Release of N[3H]Acetylaspartylglutamate from the Optic Pathway. Journal of Neurochemistry, 1988, 51, 1956-1959.	3.9	67
23	NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Current Pharmaceutical Design, 2014, 20, 5169-5179.	1.9	60
24	The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [3H]NAAG catabolism in vivo. Neuroscience Letters, 1989, 100, 295-300.	2.1	48
25	Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation. Current Pharmaceutical Design, 2014, 20, 5180-5185.	1.9	48
26	Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice. Journal of Physiology, 2005, 563, 777-793.	2.9	45
27	Immunocytochemical distribution of n-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways. Journal of Chemical Neuroanatomy, 1993, 6, 277-292.	2.1	32
28	Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse, 2009, 63, 625-635.	1.2	25
29	Assessing and Treating Cognitive Impairment in Schizophrenia: Current and Future. Current Pharmaceutical Design, 2014, 20, 5127-5138.	1.9	22
30	The glycine transporter GlyT1 controlsNâ€methylâ€Dâ€aspartic acid receptor coagonist occupancy in the mouse retina. European Journal of Neuroscience, 2009, 30, 2308-2317.	2.6	18
31	NMDA Pathology and Treatment of Schizophrenia. Current Pharmaceutical Design, 2014, 20, 5118-5126.	1.9	18
32	Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease. Brain Research, 1993, 629, 305-309.	2.2	14
33	Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission. Recent Patents on CNS Drug Discovery, 2009, 4, 220-238.	0.9	12
34	Promoter analysis of human glutamate carboxypeptidase II. Brain Research, 2007, 1170, 1-12.	2.2	4
35	Editorial (Thematic Issue: Regulating the CNS Grand Regulator; N-methyl-D-aspartate) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 1	1.9	0